In line with this hypothesis, LSD1 was described as a critical regulator of LSCs potential in a mouse model of MLL-AF9-driven AML (16), by binding to genomic loci controlled by MLL–AF9 and promoting the expression of oncogenic gene expression signatures while inhibiting differentiation and apoptosis. Here, KMT2A is linked to acute myeloid leukemia.